(-) -Enitociclib

• Description:

  (-) -Enitociclib ((R) -Enitociclib) is an enantiomer of Enitociclib (HY-103019E) with an optical rotation of (-) . Enitociclib is a selective CDK9 inhibitor and apoptosis inducer. Enitociclib inhibits CDK9 activity and reduces the phosphorylation of Ser2 in the carboxyl-terminal domain (CTD) of RNA polymerase Pol II, thereby downregulating the transcription of key oncogenes such as MYC and MCL1. Enitociclib has anti-proliferative activity targeting MYC+ lymphoma and multiple myeloma (MM) cells, and has synergistic effects with Bortezomib (HY-10227) and Lenalidomide (HY-A0003), and can be used in the research of hematological malignancies[1][2].

• Product Name Alternative:

  (R) -Enitociclib; (-) -BAY-1251152; (-) -VIP152

• UNSPSC:

  12352005

• Target:

  Apoptosis; CDK; DNA/RNA Synthesis; Drug Isomer

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/minus-enitociclib.html

• Purity:

  99.85

• Solubility:

  DMSO : 22 mg/mL (ultrasonic)

• Smiles:

  COC1=C(C2=C(F)C=NC(NC3=CC(C[S@](C)(=N)=O)=CC=N3)=C2)C=CC(F)=C1

• Molecular Formula:

  C19H18F2N4O2S

• Molecular Weight:

  404.43

• References & Citations:

  [1]Frigault MM, et al. Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated Transcription. Cancer Res Commun. 2023 Nov 9;3 (11) :2268-2279.|[2]Tran S, et al. Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma[J]. Blood Neoplasia, 2025, 2 (1) : 100050.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  CDK9

• CAS Number:

  [1610408-96-2]